Longevity Health Holdings, Inc. Annual Report: A Simple Guide

I’ve put together this guide to help you understand how Longevity Health Holdings performed this year. My goal is to turn complex financial filings into plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Longevity Health Holdings (formerly Carmell) now focuses entirely on "bio-aesthetics." They have moved away from bone and tissue research to sell skincare and hair-care products. Their main line, Elevai, uses "exosome" technology—tiny particles from stem cells—marketed for anti-aging and hair restoration. They sell directly to doctors and consumers, aiming to capture a share of the premium skincare market.

2. Major Leadership Shake-up

As of March 2026, long-time CEO and Chairman Rajiv Shukla stepped down. Janakiram Ajjarapu, the managing member of International Capital Partners (ICP), replaced him. This move signals a shift toward a more aggressive, finance-focused management style. Since ICP provides most of the company’s funding, the new leadership is now directly tied to the company’s primary source of cash.

3. Financial Health: Still "Cash-Hungry"

The company is in a high-growth phase and currently operates at a loss while trying to scale the Elevai brand. They rely on private investors to fund operations. In March 2026, they raised $200,000 by selling 690,000 shares to ICP at roughly $0.29 per share.

What this means for you: The company frequently issues new shares to raise cash. This process, called dilution, means your "slice of the pie" gets smaller every time they do it. With only about 2.47 million shares available, this is a very small company. Because so few shares exist, even small trades can cause the stock price to swing wildly.

4. Major Wins and Challenges

• Wins: The acquisition of the Elevai line in 2025 is now the company's primary revenue driver. By focusing on high-end skincare, they are transitioning from research-heavy operations to a product-sales model.
• Challenges: The company carries legacy costs, including a $360,000 severance package for the former CEO and a $480,000 "success bonus" triggered by capital raises. These fixed costs create significant pressure to grow sales quickly.

5. Key Risks

• Dilution: The company must sell shares to maintain operations. If they do not reach profitability soon, they will likely sell more shares, which lowers the value of current holdings.
• Leadership Transition: The change in executive leadership creates uncertainty. Investors should monitor whether the new team can successfully drive product sales rather than just managing debt.
• Market Size: With a total value of about $3.3 million, this is a highly speculative investment. The company lacks the cash reserves of larger competitors, making them vulnerable to market shifts.

6. Future Outlook

The company’s future depends entirely on the market adoption of Elevai products. If you are considering an investment, watch their quarterly reports for two specific metrics: revenue growth (are sales rising?) and cash burn (how long until they need more money?). Expect continued volatility as the company attempts to transform into a successful skincare business.

Investor Tip: Before making a decision, check the latest SEC filings for any new "Form 4" or "8-K" reports. These will tell you immediately if the company is issuing more shares or if there are further changes in leadership.